Dimitrios Varrias, MD
Clinical FellowAbout
Research
Publications
2026
Clinical predictors of long-term atrial fibrillation recurrence post catheter ablation: an ITHACA-database analysis.
Leavitt J, Varrias D, Gasparis C, Wolf E, Zafeiropoulos S, Zimmer A, Epstein L, Coleman K, Mountantonakis S. Clinical predictors of long-term atrial fibrillation recurrence post catheter ablation: an ITHACA-database analysis. Journal Of Invasive Cardiology 2026 PMID: 41538776, DOI: 10.25270/jic/25.00273.Peer-Reviewed Original ResearchLong-term AF recurrenceAF recurrencePatient baseline demographicsCatheter ablationAtrial fibrillationComposite outcomeAssociated with long-term AF recurrenceEfficacy of catheter ablationLong-term success rateArea under the curveFollow-up visitMultivariate logistic regressionIndividual risk scoresIndividual risk predictionBaseline demographicsAblation outcomesTreatment optionsRecurrenceRisk factorsMedical recordsRisk scoreElectronic medical recordsPatientsSuccess rateLogistic regression
2025
Long-Term Outcomes Beta-Blocker Use and Permanent Pacing in Patients With Heart Failure Preserved Ejection Fraction
Gabriels J, Coleman K, Fishbein J, Cunn G, Bekiaridou A, Varrias D, Sharma N, Mokhtari M, George R, Brennan C, Gandomi A, Vullaganti S, Epstein L, Mountantonakis S. Long-Term Outcomes Beta-Blocker Use and Permanent Pacing in Patients With Heart Failure Preserved Ejection Fraction. JACC Advances 2025, 5: 102425. PMID: 41401684, PMCID: PMC12769800, DOI: 10.1016/j.jacadv.2025.102425.Peer-Reviewed Original ResearchLow risk of mortalityRisk of mortalityPreserved Ejection FractionBeta-blockersLong-term outcomesLow riskCohort studyEjection fractionPermanent pacingEmergency department visitsNorthwell Health SystemBeta-blocker therapyBeta-blocker useRetrospective cohort studyHealth systemDepartment visitsOutcome of pacingMortality burdenHospital readmissionPrimary outcomeHeart failureHFpEFMortality benefitPatientsTherapyLeveraging Implantable Cardiac Defibrillator Remote Transmissions to Predict the Occurrence of Atrial Fibrillation
Scheid M, Coleman K, Mullane S, Varrias D, Mountantonakis E, Husk G, Bhasin K, Skipitaris N, Epstein L, Zanos T, Mountantonakis S. Leveraging Implantable Cardiac Defibrillator Remote Transmissions to Predict the Occurrence of Atrial Fibrillation. Journal Of Cardiovascular Electrophysiology 2025, 36: 2903-2909. PMID: 40916235, DOI: 10.1111/jce.70072.Peer-Reviewed Original ResearchMeSH KeywordsAction PotentialsAgedAtrial FibrillationDecision Support TechniquesDefibrillators, ImplantableElectric CountershockFemaleHeart FailureHeart RateHumansMachine LearningMaleMiddle AgedPredictive Value of TestsPrimary PreventionProspective StudiesRemote Sensing TechnologyReproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsDaily remote monitoringArea under the receiver operating characteristic curveAtrial fibrillationAF occurrenceHeart failureOccurrence of atrial fibrillationMedian ejection fractionPrimary prevention ICDReal-world cohortDevelopment of AFReceiver operating characteristic curveMonths post-implantOperating characteristics curveParoxysmal AFEjection fractionMedian ageIschemic cardiomyopathyClinical trialsHF decompensationPost-implantRisk prediction algorithmsSensing amplitudePatientsCharacteristic curveAUCIschaemic cerebrovascular events post-atrial fibrillation catheter ablation: a descriptive report on the ITHACA database
Leavitt J, Nunez-Baez S, Varrias D, Kleiman J, Gasparis C, Coleman K, Mountantonakis S. Ischaemic cerebrovascular events post-atrial fibrillation catheter ablation: a descriptive report on the ITHACA database. European Heart Journal - Quality Of Care And Clinical Outcomes 2025, qcaf094. PMID: 40853222, DOI: 10.1093/ehjqcco/qcaf094.Peer-Reviewed Original ResearchThe Impact of Diagnostic Code and Inclusion Period on Clinical Outcomes in ATTR Cardiomyopathy
Lee P, Chi K, Lin Y, Varrias D, Patel S. The Impact of Diagnostic Code and Inclusion Period on Clinical Outcomes in ATTR Cardiomyopathy. JACC Advances 2025, 4: 101918. PMID: 40713144, PMCID: PMC12418417, DOI: 10.1016/j.jacadv.2025.101918.Commentaries, Editorials and LettersDifferences in intravascular hemolysis between 2 technologies for pulse field ablation of atrial fibrillation
Mountantonakis S, Beccarino N, Goyal A, Ferrick N, Varrias D, Baez S, Calvo A, Kruger S, Alshenawy M, Leavitt J, Sharma N, Jia K, Vele O, Abrams M, Choudry S, Krumerman A, Skipitaris N, Bhasin K, Coleman K. Differences in intravascular hemolysis between 2 technologies for pulse field ablation of atrial fibrillation. Heart Rhythm 2025, 23: e217-e219. PMID: 40675312, DOI: 10.1016/j.hrthm.2025.07.018.Peer-Reviewed Original ResearchAnticoagulants for Atrial Fibrillation in Survivors of Intracranial Hemorrhage A Meta-Analysis of Randomized Trials
Chi K, Chang Y, Lee P, Rossi R, Lin Y, Akman Z, Varrias D, Damluji A, Nanna M. Anticoagulants for Atrial Fibrillation in Survivors of Intracranial Hemorrhage A Meta-Analysis of Randomized Trials. Journal Of The American College Of Cardiology 2025, 86: 287-290. PMID: 40701674, PMCID: PMC12758899, DOI: 10.1016/j.jacc.2025.04.069.Peer-Reviewed Original ResearchCatheter-Based Therapies in Acute Pulmonary Embolism—Mortality and Safety Outcomes: A Systematic Review and Meta-Analysis
Zoumpourlis P, Mangeshkar S, Chi K, Varrias D, Spanos M, Fahimuddin M, Langston M, Khan U, Grushko M, Singh P, Sokol S. Catheter-Based Therapies in Acute Pulmonary Embolism—Mortality and Safety Outcomes: A Systematic Review and Meta-Analysis. Journal Of Clinical Medicine 2025, 14: 4167. PMID: 40565913, PMCID: PMC12194266, DOI: 10.3390/jcm14124167.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCatheter-based therapiesIntermediate-risk PEHigh-risk PECatheter-directed thrombolysisMajor bleedingPulmonary embolismIntracranial hemorrhageCrude incidenceSafety outcomesSystemic thrombolysisRight ventricular (RV) dysfunctionConclusions:Mechanical thrombectomyResults:Meta-analysisMidterm all-cause mortalityAll-Cause MortalityCompare short-termIncidence of mortalityAcute PERV hemodynamicsMinor bleedingMidterm mortalityMortality benefitTreatment strategiesGLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance
Chi K, Song J, Desphande S, Lee P, Soni A, Gonzales-Uribe A, Lessa Y, Morgan A, Chang Y, Lin Y, Akman Z, Nouri A, Rossi R, Babapour G, Varrias D, Parker T, Baldassarre L, Jha A, Muchtar E, Hull S, Kwan J, Nanna M. GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance. JAMA Network Open 2025, 8: e2517541. PMID: 40587132, PMCID: PMC12210086, DOI: 10.1001/jamanetworkopen.2025.17541.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1GLP-1 RAsNew-onset HFAcute kidney injuryEnd-stage kidney diseaseScore matching analysisPrimary preventionMonoclonal gammopathyTransient ischemic attackCohort studyDecompensated HFMGUS diagnosisRA usersKidney injuryHeart failureRA useKidney diseaseIschemic attackEffects of GLP-1 RAsMajor adverse cardiovascular eventsProspective randomized trialsSecondary end pointsRisk of cardiovascular diseaseRetrospective cohort studyAdverse cardiovascular eventsUnrecognized actionable cardiac arrhythmias in patients with moderate to severe chronic obstructive pulmonary Disease: Can continuous monitoring unmask the culprit
Coleman K, Varrias D, Wolf E, Schwartz J, Garcia B, Roselli V, Lam B, Leavitt J, Sharma N, Dumchin G, Altschul E, Oks M, Mina B, Mountantonakis S. Unrecognized actionable cardiac arrhythmias in patients with moderate to severe chronic obstructive pulmonary Disease: Can continuous monitoring unmask the culprit. Respiratory Medicine 2025, 245: 108190. PMID: 40451548, DOI: 10.1016/j.rmed.2025.108190.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseModerate-severe COPDObstructive pulmonary diseaseIndependent predictorsPulmonary diseaseControl group of patientsBeta-agonist inhalersModerate to severe chronic obstructive pulmonary diseaseRight heart failureSevere chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease patientsControl groupGroup of patientsEP interventionProspective cohort studyChronic kidney diseaseImplantable cardiac defibrillatorImplant indicationsArrhythmic riskILR implantationCatheter ablationNear syncopePermanent pacemakerArrhythmic eventsEligible patients